Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A-PREDICT: A Phase II Study Of Axitinib In Metastatic Renal Cell Cancer in Patients Unsuitable for Nephrectomy

NCT01693822 is registered in ClinicalTrials.gov with Institute of Cancer Research, United Kingdom as lead sponsor.

NCT NCT01693822
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01693822 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A-PREDICT: A Phase II Study Of Axitinib In Metastatic Renal Cell Cancer in Patients Unsuitable for Nephrectomy
Lead sponsor
Institute of Cancer Research, United Kingdom
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2012
Completion date
February 28, 2022
Enrollment
65 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

clear-cell metastatic renal cell carcinoma